Ocular infections:
Indications for: BESIVANCE
Susceptible bacterial conjunctivitis.
Clinical Trials:
In a randomized, double-masked, vehicle-controlled, multicenter clinical trial, in which patients 1-98 years of age were dosed 3 times a day for 5 days, Besivance was superior to vehicle in patients with bacterial conjunctivitis.
Clinical resolution was achieved in 45% (n=90/198) for the Besivance-treated group vs 33% (n=63/191) for the vehicle-treated group (difference 12%; 95% CI, 3-22).
Microbiological outcomes demonstrated a statistically significant eradication rate for causative pathogens of 91% (n=181/198) for the Besivance-treated group vs 60% (n=114/191) for the vehicle-treated group (difference 31%; 95% CI, 23-40).
Microbiologic eradication does not always correlate with clinical outcome in anti-infective trials.
Adults and Children:
<1yr: not established. ≥1yr: 1 drop in affected eye(s) 3 times daily (4–12hrs apart) for 7 days. Shake bottle once before use.
BESIVANCE Warnings/Precautions:
Not for inj into the eye. Avoid contact lenses during therapy or if symptomatic. Prolonged use may result in overgrowth of nonsusceptible organisms. Pregnancy. Nursing mothers.
BESIVANCE Classification:
Quinolone.
Adverse Reactions:
Conjunctival redness, blurred vision, eye pain/pruritus/irritation, headache; superinfection (discontinue and treat).
Drug Elimination:
The average elimination half-life of besifloxacin in plasma following multiple dosing was estimated to be 7 hours.
How Supplied:
Susp—5mL
